Telmisartan for the management of patients at high cardiovascular risk

Current Medical Research and Opinion

Volumn 27, Issue 8, 2011, Pages 1673-1682

  Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiotensin II receptor blocker; Cardiovascular disease; Cardiovascular risk; Renin angiotensin system; Telmisartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; HYDROCHLOROTHIAZIDE; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HEART DEATH; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; LIPOPHILICITY; MEDLINE; META ANALYSIS (TOPIC); PATIENT COMPLIANCE; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; COST OF ILLNESS; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; PUBMED; RAMIPRIL; TIME FACTORS;

EID: 79960426099     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.597378     Document Type: Review

References (74)

1. Mathers CD, Loncar D. Projects of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
2. Ezzati M. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003;362:271-80. (Pubitemid 36936837)
3. Petersen S, Peto V, Rayner M, et al. European Cardiovascular Disease Statistics. BHF: London, 2005.
4. Leal J, Luengo-Ferná ndez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-19. (Pubitemid 43954923)
5. Lawes CM, Vander Hoom S, Rodgers A; International Society of Hypertension. Global burden of blood pressure-related disease, 2001. Lancet 2008;371:1513-18. (Pubitemid 351626187)
6. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57. (Pubitemid 43767064)
7. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13. (Pubitemid 35472129)
8. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87. (Pubitemid 46924065)
9. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206. (Pubitemid 46465728)
10. Capewell S, Murphy NF, MacIntyre K, et al. Short-term and long-term outcomes in 133,429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990-2000: population-based cohort study. Heart 2006;92:1563-70. (Pubitemid 44629156)
11. Dhamoon MS, Sciacca RR, Rundek T, et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006;66:641-6. (Pubitemid 43739815)
12. Cea-Calvo L, Conthe P, Gó mez-Ferná ndez-Pé rez C; RICARHD Investigators. Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study. Cardiovasc Diabetol 2006;5:23.
13. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52. (Pubitemid 39208455)
14. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244-63.
15. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114:2850-70. (Pubitemid 46018288)
16. Bakris G, Böhm M, Dagenais G, et al. Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol 2008;97:713-25.
17. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78.
18. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-88.
19. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360:129-39.
20. Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005;28:385-407. (Pubitemid 41014801)
21. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
22. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17. (Pubitemid 38031904)
23. Wong ND, Lopez VA, L'Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007;167:2431-6. (Pubitemid 350254901)
24. Mustone Alexander L. Desirable therapeutic characteristics of an optimal antihypertensive agent. Drugs 2006;66:1239-52.
25. Mulcahy D. Circadian variation in cardiovascular events. Blood Press Monit 1998;3:29-34. (Pubitemid 28181627)
26. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007;369:1208-19. (Pubitemid 46527856)
27. Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33. (Pubitemid 47310975)
28. Morawietz H. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS Trial. Circulation 2006;114:1S-296S.
29. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89(Suppl):3A-10A. (Pubitemid 34143240)
30. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92. (Pubitemid 28496194)
31. Chen R, Iwai M, Wu L, et al. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 2003;42:542-7. (Pubitemid 37237351)
32. Hanon S, Vijayaraman P, Sonnenblick EH, et al. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst 2000;1:147-50.
33. Crowley SD, Gurley SB, Coffman TM. AT(1) receptors and control of blood pressure: the kidney and more. . . Trends Cardiovasc Med 2007;17:30-4. (Pubitemid 46038770)
34. Gendron L, Payet MD, Gallo-Payet N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J Mol Endocrinol 2003;31:359-72. (Pubitemid 38054511)
35. Steckelings UM, Kaschina E, Unger T. The AT2 receptor-a matter of love and hate. Peptides 2005;26:1401-9. (Pubitemid 41021474)
36. Ahimastos AA, Natoli AK, Lawler A, et al. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005;45:1194-9. (Pubitemid 40770326)
37. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8. (Pubitemid 44209181)
38. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53. (Pubitemid 30051645)
39. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):169S-73S. (Pubitemid 43265218)
40. Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008;51:1624-30.
41. Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008;51:1465-7.
42. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-7. (Pubitemid 44455166)
43. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499-509. (Pubitemid 39469033)
44. Chaput AJ. Persistence with angiotensin receptor blockers (ARB) versus other antihypertensives (AHT) using the Saskatchewan database. Can J Cardiol 2000;16(Suppl F):194A.
45. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75. (Pubitemid 33126822)
46. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906. (Pubitemid 37409706)
47. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66. (Pubitemid 37093915)
48. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59. (Pubitemid 351522739)
49. Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25:41-6. (Pubitemid 40571342)
50. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-67. (Pubitemid 30648951)
51. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press Suppl 2001;1:6-11. (Pubitemid 32288980)
52. Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002;302:1089-95. (Pubitemid 34920230)
53. Burnier M. Telmisartan: a different angiotensin receptor blocker protecting a different population? J Int Med Res 2009;37:1662-79.
54. Stangier J, Schmid J, Tü rck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers. J Clin Pharmacol 2000;40(12 Pt 1):1312-22.
55. Bakris G, Burgess E, Weir M, et al.; AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008;74:364-9. (Pubitemid 352002795)
56. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med 2003;348:2407-15. (Pubitemid 36682819)
57. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-83. (Pubitemid 40525142)
58. Lacourciè re Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9:203-10. (Pubitemid 39159163)
59. Lacourciè re Y, Neutel JM, Davidai G, et al. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19:104-12. (Pubitemid 43217044)
60. Sharma AM, Davidson J, Koval S, et al. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007;6:28.
61. White WB, Davidai G, Schumacher H. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. J Hum Hypertens 2009; 23:817-25.
62. Lacourciè re Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005;27:1795-805. (Pubitemid 41815230)
63. Littlejohn 3rd TW, Majul CR, Olvera, R et al.; Study Investigators. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:207-13.
64. Neutel JM, et al. Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: TEAMSTA Severe HTN Study. J Clin Hypertens 2010;7:537.
65. White WB, Littlejohn TW, Majul CR, et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010;15:205-12.
66. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598-605.
67. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239-45. (Pubitemid 47400613)
68. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26:819-24. (Pubitemid 351354932)
69. Costa FV, Esposti LD, Cerra C, et al. Trends in prescription and determinants of persistence to antihypertensive therapy. The PAPEETE Study. High Blood Press Cardiovasc Prev 2009;16:1-10.
70. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008;1:32-40.
71. Electronic Medicines Compendium (eMC). Summary of Product Characteristics. Available at: http://emc.medicines.org.uk.
72. European Medicines Agency. Summary of Product Characteristics. Available at: http://www.emea.europa.eu.
73. Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
74. TRANSCEND Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372:1174-83